Neuronostics develops BioEP, a patented digital biomarker platform for epilepsy diagnosis and prognosis. BioEP analyses background EEG activity using eight predefined computational biomarkers derived from peer-reviewed neuroscience, providing objective clinical decision support when routine EEG is inconclusive. The platform is UKCA-marked (UK), MOHAP-cleared (UAE), ISO 13485 certified and is pursuing FDA clearance via the De Novo pathway. Neuronostics was named Most Transformative HealthTech Company at the OBN Awards 2025 and won the Epilepsy Foundation of the USA Shark Tank Competition in 2024.